XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Net sales $ 553,979 $ 551,519
Cost of goods sold 242,217 249,316
Gross profit 311,762 302,203
Selling, general and administrative expense 207,581 209,130
Research and Development Expense 47,575 49,427
Segment profit (loss) 56,606 43,646
Interest expense 5,986 5,782
Foreign exchange (gains) losses, net 1,280 1,254
Unrealized Gain on Securities (1,059,230) (815,934)
Nonoperating Income (Expense) 18,696 11,145
Income before income taxes 1,127,266 863,689
(Provision) benefit for income taxes (262,071) (206,915)
Net income attributable to Bio-Rad $ 865,195 $ 656,774
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ 29.03 $ 22.05
Weighted average common shares - basic 29,801 29,787
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ 28.74 $ 21.77
Weighted average common shares - diluted 30,104 30,171